Reports of Biochemistry
and Molecular Biology
Thu, Nov 21, 2024
[Archive]
Volume 12, Issue 1 (Vol.12 No.1 Apr 2023)
rbmb.net 2023, 12(1): 83-91 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rezaei A, Shayan N, Shirazinia S, Mollazadeh S, Ghiyasi-Moghaddam N. The Prognostic Significance of P16 Immunohistochemical Expression Pattern in Women with Invasive Ductal Breast Carcinoma. rbmb.net 2023; 12 (1) :83-91
URL: http://rbmb.net/article-1-1149-en.html
URL: http://rbmb.net/article-1-1149-en.html
Department of Pathology, Faculty of Medicine, Islamic Azad University, Mashhad Branch, Mashhad, Iran.
Abstract: (1496 Views)
Background: Breast cancer is the most common malignancy in women worldwide. The p16 protein is a cell cycle regulator and tumor suppressor implicated in several types of cancers. However, its relationship to breast cancer is still unknown. The present study aimed to assess the association of p16 protein expression with clinicopathological features in breast cancer.
This study aimed to investigate the anti-cancer effects of different gum extracts on metabolic changes and their impact on gene expression in HT-29 cell.
Methods: The study enrolled 100 patients with invasive ductal carcinoma. The samples were collected before any adjuvant chemotherapy, and p16 protein expression was determined using immunohistochemistry. Clinicopathological features were obtained from the patient’s medical records.
Results: Our findings demonstrated that p16 protein expression increased in estrogen receptor-positive tumor tissues (P< 0.01). However, no significant correlation was found between the p16 protein expression and the other clinicopathological features.
Conclusions: Our study demonstrated that p16 protein expression increased in ER-positive tumor tissue from patients with invasive ductal breast carcinoma. However, no correlation was found between the p16 protein expression and the other clinicopathological features.
This study aimed to investigate the anti-cancer effects of different gum extracts on metabolic changes and their impact on gene expression in HT-29 cell.
Methods: The study enrolled 100 patients with invasive ductal carcinoma. The samples were collected before any adjuvant chemotherapy, and p16 protein expression was determined using immunohistochemistry. Clinicopathological features were obtained from the patient’s medical records.
Results: Our findings demonstrated that p16 protein expression increased in estrogen receptor-positive tumor tissues (P< 0.01). However, no significant correlation was found between the p16 protein expression and the other clinicopathological features.
Conclusions: Our study demonstrated that p16 protein expression increased in ER-positive tumor tissue from patients with invasive ductal breast carcinoma. However, no correlation was found between the p16 protein expression and the other clinicopathological features.
Type of Article: Original Article |
Subject:
Molecular Biology
Received: 2023/02/26 | Accepted: 2023/05/8 | Published: 2023/08/15
Received: 2023/02/26 | Accepted: 2023/05/8 | Published: 2023/08/15
References
1. Katuwal S, Jousilahti P, Pukkala E. Causes of death among women with breast cancer: A follow‐up study of 50 481 women with breast cancer in Finland. Int J Cancer. 2021;149(4):839-45. [DOI:10.1002/ijc.33607] [PMID]
2. Hasan SAW. World Health Organization WHO Regional websites. Primary health care. 2021.
3. Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast cancer: epidemiology and etiology. Cell Biochem Biophys. 2015;72(2):333-8. [DOI:10.1007/s12013-014-0459-6] [PMID]
4. Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M. Genetic susceptibility to breast cancer. Mol Onc. 2010;4(3):174-91. [DOI:10.1016/j.molonc.2010.04.011] [PMID] [PMCID]
5. Choi J, Jia G, Wen W, Tao R, Long J, Shu X-O, et al. Associations of genetic susceptibility to 16 cancers with risk of breast cancer overall and by intrinsic subtypes. Hum Gen Genom Adv. 2022;3(1):100077. [DOI:10.1016/j.xhgg.2021.100077] [PMID] [PMCID]
6. Bal A, Joshi K. Pathology of Breast Cancer. Breast Cancer: Springer; 2022: 125-38. [DOI:10.1007/978-981-16-4546-4_8]
7. Scully OJ, Bay B-H, Yip G, Yu Y. Breast cancer metastasis. Cancer Genom Proteom. 2012;9(5):311-20.
8. Oppenheimer SB. Cellular basis of cancer metastasis: A review of fundamentals and new advances. Acta histochemica. 2006;108(5):327-34. [DOI:10.1016/j.acthis.2006.03.008] [PMID]
9. Lüönd F, Tiede S, Christofori G. Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. Br J Cancer. 2021;125(2):164-75. [DOI:10.1038/s41416-021-01328-7] [PMID] [PMCID]
10. Zhao X, Yang X, Fu L, Yu K. Associations of Estrogen Receptor, Progesterone Receptor, Human Epidemic Growth Factor Receptor-2 and Ki-67 with Ultrasound Signs and Prognosis of Breast Cancer Patients. Cancer Manag Res. 2021;13:4579. [DOI:10.2147/CMAR.S276422] [PMID] [PMCID]
11. Choi SB, Park JM, Ahn JH, Go J, Kim J, Park HS, et al. Abstract P2-08-13: The prognostic significance of Ki67 and progesterone receptor; could they really have prognostic importance in early breast cancer with estrogen receptor positive, HER-2 negative?. Cancer Res. 2022; 82 (4_Supplement): P2-08-13. [DOI:10.1158/1538-7445.SABCS21-P2-08-13]
12. Xia Y, Liu Y, Yang C, Simeone DM, Sun T-T, DeGraff DJ, et al. Dominant role of CDKN2B/p15INK4B of 9p21. 3 tumor suppressor hub in inhibition of cell-cycle and glycolysis. Nat commun. 2021;12(1):1-15. [DOI:10.1038/s41467-021-22327-5] [PMID] [PMCID]
13. Spiliopoulou P, Yang SYC, Bruce JP, Wang BX, Berman HK, Pugh TJ, Siu LL. All is not lost: learning from 9p21 loss in cancer. Trends Immunol. 2022;43(5):379-390. [DOI:10.1016/j.it.2022.03.003] [PMID]
14. Hume S, Dianov GL, Ramadan K. A unified model for the G1/S cell cycle transition. Nucleic Acids Res. 2020;48(22):12483-501. [DOI:10.1093/nar/gkaa1002] [PMID] [PMCID]
15. Julve M, Clark JJ, Lythgoe MP. Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma. Expert Opin Pharmaco. 2021;22(3):351-61. [DOI:10.1080/14656566.2020.1828348] [PMID]
16. Shigemasa K, Hu C, West C, Clarke J, Pharham G, Parmley T, et al. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma. J Soc Gynecol Invest. 1997;4(2):95-102.
https://doi.org/10.1177/107155769700400209 [DOI:10.1016/S1071-5576(97)81110-0]
17. Mai S, Welzel G, Ottstadt M, Lohr F, Severa S, Prigge E-S, et al. Prognostic relevance of HPV infection and p16 overexpression in squamous cell anal cancer. nt J Rad Oncol Biol Phys. 2015;93(4):819-27. [DOI:10.1016/j.ijrobp.2015.08.004] [PMID]
18. Milde-Langosch K, Bamberger A-M, Rieck G, Kelp B, Löning T. Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat. 2001;67(1):61-70. [DOI:10.1023/A:1010623308275] [PMID]
19. Hashmi AA, Naz S, Hashmi SK, Hussain ZF, Irfan M, Khan EY, et al. Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer. BMC Clin Pathol. 2018;18(1):1-11. [DOI:10.1186/s12907-018-0077-0] [PMID] [PMCID]
20. El-shaarawy F, Abo ElAzm MM, Mohamed RH, Radwan MI, Abo-Elmatty DM, Mehanna ET. Relation of the methylation state of RUNX3 and p16 gene promoters with hepatocellular carcinoma in Egyptian patients. Egypt J Med Hum Genet. 2022;23(1):1-9. [DOI:10.1186/s43042-022-00256-2]
21. Inoue K, Fry EA. Aberrant expression of p14ARF in human cancers: A new biomarker? Tumor microenvironment. 2018;1(2):37. [DOI:10.4103/tme.tme_24_17] [PMID] [PMCID]
22. Salih MM, Higgo AA, Eed EM. Prognostic Significance of p16 Protein Expression in Breast Cancer. in vivo. 2022;36(1):336-40. [DOI:10.21873/invivo.12707] [PMID] [PMCID]
23. Shrestha B, Dunn L. The declaration of helsinki on medical research involving human subjects: A review of seventh revision. J J Nepal Health Res Council. 2019;17(4):548-52. [DOI:10.33314/jnhrc.v17i4.1042] [PMID]
24. Lee K, Jung ES, Choi Y-J, Lee KY, Lee A. Expression of pRb, p53, p16 and cyclin D1 and their clinical implications in urothelial carcinoma. J Korean Med Sci. 2010;25(10):1449-55.
https://doi.org/10.3346/jkms.2010.25.10.1449 [DOI:10.3346/jkms.2013.28.10.1449] [PMID] [PMCID]
25. Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22(6):1014-24. [DOI:10.1200/JCO.2004.03.118] [PMID]
26. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn H-J. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736-47. [DOI:10.1093/annonc/mdr304] [PMID] [PMCID]
27. Park JW, Kang J, Lim KY, Kim H, Kim S-I, Won JK, et al. The prognostic significance of p16 expression pattern in diffuse gliomas. J Transl Med. 2021;55(2):102. [DOI:10.4132/jptm.2020.10.22] [PMID] [PMCID]
28. Rambau PF, Vierkant RA, Intermaggio MP, Kelemen LE, Goodman MT, Herpel E, et al. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. J Pathol Clin Res. 2018;4(4):250-61. [DOI:10.1002/cjp2.109] [PMID] [PMCID]
29. Witkiewicz AK, Knudsen KE, Dicker AP, Knudsen ES. The meaning of p16ink4a expression in tumors: functional significance, clinical associations and future developments. Cell cycle. 2011;10(15):2497-503. [DOI:10.4161/cc.10.15.16776] [PMID] [PMCID]
30. Shin E, Jung W-H, Koo J-S. Expression of p16 and pRB in invasive breast cancer. Int J Clin Exp Pathol. 2015;8(7):8209.
31. Golmohammadi R, Elyasi H. Relationship between P16 expression and breast cancer using histology and immunohistochemistry. J Mazandaran Uni Med Sci. 2017;27:181-186.
32. Zhang S-L, Wang Y-Q, Zhang J-H, Hu J-W, Ma J, Gu Z, et al. Methylated p16 gene is associated with negative expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in breast cancer. Eur J Gynaecol Oncol. 2021;42(3):530-6. [DOI:10.31083/j.ejgo.2021.03.2173]
33. Peurala E, Koivunen P, Haapasaari K-M, Bloigu R, Jukkola-Vuorinen A. The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. Breast Cancer Res. 2013;15(1):1-10. [DOI:10.1186/bcr3376] [PMID] [PMCID]
34. Shan M, Zhang X, Liu X, Qin Y, Liu T, Liu Y, et al. P16 and p53 play distinct roles in different subtypes of breast cancer. PloS one. 2013;8(10):e76408. [DOI:10.1371/journal.pone.0076408] [PMID] [PMCID]
35. Pare R, Shin JS, Lee CS. Increased expression of senescence markers p14ARF and p16INK4a in breast cancer is associated with an increased risk of disease recurrence and poor survival outcome. Histopathology. 2016;69(3):479-91. [DOI:10.1111/his.12948] [PMID]
36. Zhao L, Liu H. Immunohistochemical detection and clinicopathological significance of JARID1B/KDM5B and P16 expression in invasive ductal carcinoma of the breast. Genet Mol Res. 2015;14(2):5417. [DOI:10.4238/2015.May.22.11] [PMID]
37. Vohra L, Siddiqui T. Metaplastic Breast Cancer and p16 Positivity: What Does It Mean. J Carcinog Mutagene. 2015;6(6):244.
38. Lebok P, Roming M, Kluth M, Koop C, Özden C, Taskin B, et al. p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. Oncotarget. 2016;7(49):81322. [DOI:10.18632/oncotarget.13227] [PMID] [PMCID]
39. Zhu L-F. The correlation of p16 and MMPs expression in cervical secretions with the angiogenesis and cell proliferation in cervical cancer tissue. J Hainan Med Univ. 2017;23(8):130-3.
40. Bohn OL, Fuertes-Camilo M, Navarro L, Saldivar J, Sanchez-Sosa S. p16INK4a expression in basal-like breast carcinoma. Int J Clin Exp Pathol. 2010;3(6):600.
41. du Jour KS, Geller R, Dureau ZJ, Liu Y, Cohen C, Oprea-Ilies GM, editors. p16 Is Highly Expressed in TNT and Is Associated with Worse Overall Survival (OS) in All Breast Cancers (BC). Laboratory Investigation; 2016: Nature Publishing Group 75 Varick St, 9th Flr, New York, NY 10013-1917 USA.
42. Kobierzycki C, Grzegrzolka J, Glatzel-Plucinska N, Piotrowska A, Wojnar A, Smolarz B, et al. Expression of p16 and SATB1 in Invasive Ductal Breast Cancer-A Preliminary Study. In Vivo. 2018;32(4):731-6. [DOI:10.21873/invivo.11301] [PMID] [PMCID]
43. Askari M, Sobti RC, Nikbakht M, Sharma SC. Promoter hypermethylation of tumour suppressor genes (p14/ARF and p16/INK4a): case-control study in North Indian population. Mol Biol Rep. 2013;40(8):4921-8. [DOI:10.1007/s11033-013-2592-5] [PMID]
44. Bhatia K, Misra P, Soe YN, Sibin MK, Batra HS, Shelly D, et al. A pilot study on DNA hypermethylation status in promoter region of P16 gene in patients with sporadic breast cancer. Med J Armed Forces India. 2022 Jul;78(3):322-326. [DOI:10.1016/j.mjafi.2021.07.011] [PMID] [PMCID]
45. Bartova M, Ondrias F, Muy-Kheng T, Kastner M, Singer Ch, Pohlodek K. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component. Bratisl Lek Listy. 2014;115(7):445-51. [DOI:10.4149/BLL_2014_088] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
